NO20021407L - Biphenyl derivatives used as NHE-3 inhibitors - Google Patents

Biphenyl derivatives used as NHE-3 inhibitors

Info

Publication number
NO20021407L
NO20021407L NO20021407A NO20021407A NO20021407L NO 20021407 L NO20021407 L NO 20021407L NO 20021407 A NO20021407 A NO 20021407A NO 20021407 A NO20021407 A NO 20021407A NO 20021407 L NO20021407 L NO 20021407L
Authority
NO
Norway
Prior art keywords
nhe
inhibitors
derivatives used
biphenyl derivatives
biphenyl
Prior art date
Application number
NO20021407A
Other languages
Norwegian (no)
Other versions
NO20021407D0 (en
Inventor
Dieter Dorsch
Peter Raddatz
Norbert Beier
Claudia Wilm
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20021407D0 publication Critical patent/NO20021407D0/en
Publication of NO20021407L publication Critical patent/NO20021407L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
NO20021407A 1999-09-22 2002-03-21 Biphenyl derivatives used as NHE-3 inhibitors NO20021407L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19945302A DE19945302A1 (en) 1999-09-22 1999-09-22 Biphenyl derivatives as NHE-3 inhibitors
PCT/EP2000/008616 WO2001021582A1 (en) 1999-09-22 2000-09-04 Biphenyl derivatives used as nhe-3 inhibitors

Publications (2)

Publication Number Publication Date
NO20021407D0 NO20021407D0 (en) 2002-03-21
NO20021407L true NO20021407L (en) 2002-03-21

Family

ID=7922831

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021407A NO20021407L (en) 1999-09-22 2002-03-21 Biphenyl derivatives used as NHE-3 inhibitors

Country Status (16)

Country Link
EP (1) EP1214291A1 (en)
JP (1) JP2004500338A (en)
KR (1) KR20020033818A (en)
CN (1) CN1555356A (en)
AU (1) AU7649700A (en)
BR (1) BR0014199A (en)
CA (1) CA2387529A1 (en)
CZ (1) CZ2002815A3 (en)
DE (1) DE19945302A1 (en)
HU (1) HUP0202891A3 (en)
MX (1) MXPA02003087A (en)
NO (1) NO20021407L (en)
PL (1) PL355097A1 (en)
SK (1) SK3342002A3 (en)
WO (1) WO2001021582A1 (en)
ZA (1) ZA200203095B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10163239A1 (en) * 2001-12-21 2003-07-10 Aventis Pharma Gmbh Substituted imidazolidines, process for their preparation, their use as medicaments or diagnostic agents, and medicaments containing them
US7049333B2 (en) 2002-06-04 2006-05-23 Sanofi-Aventis Deutschland Gmbh Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis
US20050054705A1 (en) 2003-02-04 2005-03-10 Aventis Pharma Deutschland Gmbh N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
DE10304374A1 (en) 2003-02-04 2004-08-05 Aventis Pharma Deutschland Gmbh Novel substituted 2-aminoimidazoles, process for their preparation, their use as medicament or diagnostic agent and medicament containing them
DE10341240A1 (en) 2003-09-08 2005-04-07 Aventis Pharma Deutschland Gmbh Substituted thienoimidazoles, process for their preparation, their use as medicament or diagnostic agent, and medicament containing them
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
DE102005001411A1 (en) 2005-01-12 2006-07-27 Sanofi-Aventis Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them
ATE479679T1 (en) 2007-06-28 2010-09-15 Sanofi Aventis Us Llc METHOD FOR PRODUCING N-(2-CHLORINE-4-METHYL-3-THIENYL)-1H-BENZIMIDAZOLE-2-AMINE HYDROCHLORIDE AND INTERMEDIATE PRODUCTS THEREFOR
EP2342178B1 (en) 2008-09-02 2016-09-28 Sanofi Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
LT2384318T (en) 2008-12-31 2018-02-26 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
PL2695881T3 (en) 2011-03-15 2016-11-30 Guanidine compound
CN103012200B (en) * 2011-09-20 2014-12-17 北京大学 Compound with beta-secretase inhibition function, preparation method and applications thereof
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
AU2013304812B2 (en) 2012-08-21 2016-06-09 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EP3988120A1 (en) 2013-04-12 2022-04-27 Ardelyx, Inc. Nhe3-binding compounds and methods for inhibiting phosphate transport
SG11201700398RA (en) 2014-07-25 2017-02-27 Taisho Pharmaceutical Co Ltd Phenyl tetrahydroisoquinoline compound substituted with heteroaryl
JP7292207B2 (en) 2017-01-09 2023-06-16 アルデリックス， インコーポレイテッド Compounds Useful for Treating Gastrointestinal Disorders
KR20190128626A (en) 2017-01-09 2019-11-18 알데릭스, 인코포레이티드 Inhibitors of NHE-mediated reverse transport
KR20200074085A (en) 2017-08-04 2020-06-24 알데릭스, 인코포레이티드 Glycyrrhetic acid derivatives for the treatment of hyperkalemia
CN114008065A (en) 2019-02-07 2022-02-01 阿德利克斯股份有限公司 Glycyrrhetinic acid derivatives for treating hyperkalemia
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19548812A1 (en) * 1995-12-27 1997-07-03 Hoechst Ag Use of inhibitors of the cellular Na · + · / H · + · exchanger (NHE) for the manufacture of a medicament for respiratory stimulation
DE19622222A1 (en) * 1996-06-03 1997-12-04 Hoechst Ag Use of sodium=proton exchange inhibitor
DE19737224A1 (en) * 1997-08-27 1999-03-18 Hoechst Marion Roussel De Gmbh Pharmaceutical preparation for cardiovascular treatment
DE19819548A1 (en) * 1998-04-30 1999-11-04 Merck Patent Gmbh Biphenyl derivatives

Also Published As

Publication number Publication date
JP2004500338A (en) 2004-01-08
PL355097A1 (en) 2004-03-22
KR20020033818A (en) 2002-05-07
CZ2002815A3 (en) 2002-08-14
ZA200203095B (en) 2003-09-23
SK3342002A3 (en) 2002-07-02
CN1555356A (en) 2004-12-15
WO2001021582A1 (en) 2001-03-29
DE19945302A1 (en) 2001-03-29
BR0014199A (en) 2002-05-21
EP1214291A1 (en) 2002-06-19
HUP0202891A3 (en) 2003-11-28
NO20021407D0 (en) 2002-03-21
AU7649700A (en) 2001-04-24
CA2387529A1 (en) 2001-03-29
HUP0202891A2 (en) 2003-02-28
MXPA02003087A (en) 2003-08-20

Similar Documents

Publication Publication Date Title
DK1244647T3 (en) Quinzoline derivatives as VIGF inhibitors
DK2253620T3 (en) SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN-TYROSINKINASE INHIBITORS
NO20021407L (en) Biphenyl derivatives used as NHE-3 inhibitors
NO20021239L (en) Pteridinones as kinase inhibitors
NO20024997D0 (en) 2-guanidino-4-arylquinazolines as NHE-3 inhibitors
NO20030055L (en) Colchinol derivatives as angiogenesis inhibitors
NO20023828L (en) Pyrimidin-4-one derivatives as LDL-PLA2 inhibitors
NO20030867D0 (en) Hydroxam derivatives useful as deacetylase inhibitors
NO20014483L (en) Amine derivatives as protease inhibitors
NO992725D0 (en) 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors
NO20014412L (en) Compounds useful as anti-inflammatory agents
NO20031006L (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for inhibiting cell proliferation
ATE524441T1 (en) VLA-4 INHIBITORS
NO20015065L (en) Pyrazolobenzodiazepines as CDK2 inhibitors
NO20033618L (en) Phthalayinone-piperidino derivatives as PDE-4 inhibitors
DK1097127T3 (en) Diacylhydrazine derivatives as integrin inhibitors
NO20022558D0 (en) 4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as CETP inhibitor
NO20016201D0 (en) Tienopyrimidines as phosphodiesterase inhibitors
NO20021959L (en) Tetrahydrotiopyranephthalazinone derivatives as PDE4 inhibitors
NO991994D0 (en) Substituted 4-biphenyl-4-hydroxy acid derivatives as matrix metalloprotease inhibitors
NO20023001D0 (en) Substituted piperazine derivatives as MTP inhibitors
DE60009260D1 (en) THIOPYRANDERIVATE AS MMP INHIBITORS
NO20011654L (en) Benzamide derivatives as thrombin inhibitors
DK1077945T3 (en) Isoquinolines as urokinase inhibitors
NO20020592D0 (en) Fluorine derivatives as integrin inhibitors